Hologic stock moves as Blackstone TPG buyout offer progresses

Published on 09/02/2026 at 12:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hologic stock trades in focus as investors watch a planned cash acquisition by a private equity consortium and weigh the latest reported earnings and valuation metrics.

CGI-Architekturrendering eines modernen Medizintechnik-Firmensitzes mit Glasfassade und Wasserbecken — Hologic Hauptsitz als Architektur Rendering mit Glasfassade Spiegelteich und ruhiger Plaza ISIN US4364401012, Illustration mit AI erstellt.

Hologic stock (ISIN US4364401012) is drawing renewed attention in early September 2026 as investors weigh a planned acquisition by a private equity group alongside the companys latest reported earnings and valuation metrics as of September 2, 2026.

Earnings and valuation in focus

According to recent market commentary summarizing the planned transaction, the proposed deal values Hologic at a cash consideration of 76.00 USD per share plus a contingent value right, implying a premium to previous undisturbed trading levels and giving investors a clear reference point for the stocks valuation as of September 2, 2026.

Financial data compiled from the latest available quarterly report indicate that Hologic generated revenue of 1,040.0 million USD in its most recent quarter, which represented an increase of 4.5 percent compared with the same quarter a year earlier, underlining the companys ability to grow its top line in a challenging healthcare market environment.

In the same period, Hologic reported diluted earnings per share of 1.05 USD, up from 0.98 USD a year earlier, corresponding to an earnings growth of 7.1 percent year on year and signaling ongoing operating leverage as higher revenue flows through to the bottom line.

Market reaction and peer comparison

On the market side, Hologic stock recently traded at 75.00 USD on the Nasdaq, as of the last completed trading session before September 2, 2026, reflecting a level slightly below the 76.00 USD cash portion of the proposed buyout and suggesting that investors are assigning a discount that prices in deal risk and the time value of money.

At this price, Hologic carries a market capitalization of approximately 18,000.0 million USD as of late August 2026, placing it among the larger mid cap names in the medical technology and diagnostics segment of the broader US healthcare sector.

The current share price of 75.00 USD stands close to the upper end of the companys 52 week trading range, which spans from a low of 60.00 USD to a high of 77.00 USD, illustrating how the takeover speculation and solid earnings have lifted the stock toward its recent peak.

Go deeper

More news and data on Hologic

For additional company news, regulatory filings and price sensitive announcements on Hologic, visit the topic overview and the official investor relations page.

All Hologic news on ad hoc news Investor Relations

Diagnostics and imaging portfolio

Hologic is best known for its portfolio of diagnostic assays and imaging systems, including advanced mammography platforms used in breast cancer screening and minimally invasive biopsy procedures, which contribute a significant share of the companys revenue base in its latest reported fiscal period.

Hologic stock price snapshot

With Hologic stock priced at 75.00 USD as of the last completed Nasdaq trading session before September 2, 2026, and a proposed cash offer of 76.00 USD per share on the table, the stock trades at a modest discount to the deal terms while remaining near the top of its 52 week range from 60.00 USD to 77.00 USD, underscoring how the potential buyout and steady earnings have supported the share price.